News
J&J's TAR-200 drug fails a phase 3 bladder cancer trial, but the company is still confident in the blockbuster potential of the programme.
Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback